Previous or concurrent malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer for which the patient has been previously treated and the lifetime recurrence risk is less than 30%
Inflammatory bowel disease that is uncontrolled or on active treatment (Crohn's disease, ulcerative colitis)
Diarrhea, grade 1 or greater by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, version [v] 4.0)
Neuropathy, grade 2 or greater by NCI-CTCAE, v 4.0
Serious underlying medical or psychiatric illnesses that would, in the opinion of the treating physician, substantially increase the risk for complications related to treatment
Active uncontrolled bleeding
Pregnancy or breastfeeding
Major surgery within 4 weeks
Patients with any polymorphism in UGT1A1 other than *1 or *28 (e.g, *6) will be allowed and treated as in the *28/*28 dosing group

NCT02366819_exc_T1
Condition
malignancy
NCT02366819_exc_T2
Qualifier
Previous
NCT02366819_exc_T3
Qualifier
concurrent
NCT02366819_exc_T4
Scope
Previous or concurrent
NCT02366819_exc_T5
Negation
except
NCT02366819_exc_T6
Condition
squamous cell skin cancer
NCT02366819_exc_T7
Condition
basal cell skin cancer
NCT02366819_exc_T8
Condition
cervical cancer
NCT02366819_exc_T9
Qualifier
in situ
NCT02366819_exc_T10
Qualifier
adequately treated
NCT02366819_exc_T11
Scope
basal cell or squamous cell skin cancer
NCT02366819_exc_T13
Scope
adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer
NCT02366819_exc_T14
Condition
Inflammatory bowel disease
NCT02366819_exc_T15
Qualifier
uncontrolled
NCT02366819_exc_T16
Procedure
treatment
NCT02366819_exc_T18
Condition
Crohn's disease
NCT02366819_exc_T19
Condition
ulcerative colitis
NCT02366819_exc_T20
Scope
Crohn's disease, ulcerative colitis
NCT02366819_exc_T21
Scope
Inflammatory bowel disease that is uncontrolled or on active treatment
NCT02366819_exc_T22
Condition
Diarrhea
NCT02366819_exc_T23
Measurement
National Cancer Institute Common Terminology Criteria for Adverse Events
NCT02366819_exc_T24
Value
grade 1 or greater
NCT02366819_exc_T25
Measurement
NCI-CTCAE, version [v] 4.0
NCT02366819_exc_T26
Condition
Neuropathy
NCT02366819_exc_T27
Measurement
NCI-CTCAE, v 4.0
NCT02366819_exc_T28
Value
grade 2 or greater
NCT02366819_exc_T30
Condition
bleeding
NCT02366819_exc_T31
Qualifier
Active
NCT02366819_exc_T32
Qualifier
uncontrolled
NCT02366819_exc_T34
Procedure
Major surgery
NCT02366819_exc_T35
Temporal
within 4 weeks
NCT02366819_exc_T17
Scope
uncontrolled or on active treatment